Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism
Effect of Androgel on Atherogenesis, Inflammation, Cardiovascular Risk Factors And Adiposity in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism.: a Prospective, Randomized and Controlled-Study
Sponsor: Solvay Pharmaceuticals
Terminated
Company no longer making same drug doses.
Other terminated trials from Solvay Pharmaceuticals
- Prostate Cancer · Phase PHASE2 · Aug 2012
- Acute Decompensated Heart Failure; Renal Dysfunction · Phase PHASE2 · Jan 2010
- Obsessive Compulsive Disorder · Phase PHASE4 · Apr 2009
- Hyper-Triglyceridemia · Phase PHASE4 · Mar 2009
- Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis · Phase PHASE2 · Mar 2009
Listed as NCT00467987, this NA trial focuses on Type 2 Diabetic Male With Hypogonadotrophic Hypogonadism and remains terminated or withdrawn. Sponsored by Solvay Pharmaceuticals, it has been updated 10 times since 2007, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Mar 2024 — Jul 2024 [monthly]
Terminated NA
-
Dec 2022 — Mar 2024 [monthly]
Terminated NA
Status: Unknown Status → Terminated
-
Jan 2021 — Dec 2022 [monthly]
Unknown Status NA
▶ Show 5 earlier versions
-
Jan 2020 — Jan 2021 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
-
Jun 2018 — Jan 2020 [monthly]
Recruiting NA
-
Dec 2017 — Jun 2018 [monthly]
Recruiting NA
-
Feb 2017 — Dec 2017 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Jun 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Solvay Pharmaceuticals
- University at Buffalo
For direct contact, visit the study record on ClinicalTrials.gov .